SLC5A2 and cardiovascular disorder: A third limitation is that the CW guideline may evolve over time, especially with the recently demonstrated benefits of sodium/glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 (GLP-1) for diabetes and cardiovascular diseases [53].